Dr. Philip McMillan interviews Dr. Geert Vanden Bossche | Benefits vs Risks C-19 Vaccine
5 K Views
17
Dr. Philip McMillan interviews Dr. Geert Vanden Bossche, an international vaccine developer and scientist on March 6, 2021. As described by Dr. Bossche, the long term damage the COVID-19 vaccine will have on the human immune system could devastate the world’s population. Everyone who takes the vaccine risks damage to their natural antibodies (innate immunity) leaving them vulnerable to future exposure to viruses.
https://www.deblauwetijger.com/wp-content/uploads/2021/03/Geert-vanden-Bossche-2.pdf
https://beforeitsnews.com/health/2021/03/frightening-scientific-truths-about-covid-19-vaccine-virologist-dr-geert-vanden-bossche-speaks-out-videos-3038381.html
https://thehighwire.com/videos/a-coming-covid-catastrophe/
https://childrenshealthdefense.org/defender/virologist-huge-price-covid-mass-vaccination/
Original video: https://www.youtube.com/watch?v=ZJZxiNxYLpc
Source: https://www.bitchute.com/video/6YOlam2sVNAg/
https://www.youtube.com/watch?v=bAtg85QEKGk - Geert Vanden Bossche
Geert Vanden Bossche PhD, is an internationally recognised vaccine developer having worked as the head of the Vaccine Development Office at the German Centre for Infection Research. Interview by Philip McMillan (Vejon Health)
https://www.deblauwetijger.com/wp-content/uploads/2021/03/Geert-vanden-Bossche-2.pdf
https://beforeitsnews.com/health/2021/03/frightening-scientific-truths-about-covid-19-vaccine-virologist-dr-geert-vanden-bossche-speaks-out-videos-3038381.html
https://thehighwire.com/videos/a-coming-covid-catastrophe/
https://childrenshealthdefense.org/defender/virologist-huge-price-covid-mass-vaccination/
Original video: https://www.youtube.com/watch?v=ZJZxiNxYLpc
Source: https://www.bitchute.com/video/6YOlam2sVNAg/
https://www.youtube.com/watch?v=bAtg85QEKGk - Geert Vanden Bossche
Geert Vanden Bossche PhD, is an internationally recognised vaccine developer having worked as the head of the Vaccine Development Office at the German Centre for Infection Research. Interview by Philip McMillan (Vejon Health)